" class="no-js "lang="en-US"> Biohaven - Medtech Alert
Sunday, October 01, 2023
Biohaven | Pharmtech Focus


About Biohaven


Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression.

Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.

Related Story

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 4 2022

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding […]

Pfizer to Acquire Biohaven Pharmaceuticals

May 11 2022

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the […]

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

February 25 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee […]

Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

February 14 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced positive top-line results […]